Navigation Links
VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
Date:10/19/2007

evelopment product candidates. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Contact information:

Daniel Greenleaf

President and CEO

908-766-4400 ext. 115

dan.greenleaf@vioquestpharm.com

Brian Lenz

Chief Financial Officer

908-766-4400 ext. 117

brian.lenz@vioquestpharm.com

Lisa Lindberg

VP, Investor Relations and Corporate Communications

908-766-4400 ext. 116

Lisa.lindberg@vioquestpharm.com


'/>"/>
SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Executive Leadership and CEO Announced for BiPar Sciences 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Tianyin Pharmaceutical Co Inc Provides Fiscal 2010 Guidance 49332 1Tianyin Pharmaceutical Co Inc Provides Fiscal 2010 Guidance 49332 2Tianyin Pharmaceutical Co Inc Provides Fiscal 2010 Guidance 49332 3Tianyin Pharmaceutical Co Inc Provides Fiscal 2010 Guidance 49332 4Tianyin Pharmaceutical Co Inc Provides Fiscal 2010 Guidance 49332 5Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 1Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 2Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 3HLTH Corporation and WebMD Health Corp Announce Agreement to Merge 49326 1HLTH Corporation and WebMD Health Corp Announce Agreement to Merge 49326 2HLTH Corporation and WebMD Health Corp Announce Agreement to Merge 49326 3HLTH Corporation and WebMD Health Corp Announce Agreement to Merge 49326 4HLTH Corporation and WebMD Health Corp Announce Agreement to Merge 49326 5